Helix Acquisition Corp. III (HLXC) - 10-K Summary
Business Context and Reporting Period
Company: Helix Acquisition Corp. III (HLXC)
Reporting Period: Fiscal year ended December 31, 2025 (Inception: September 10, 2025)
Business Type: Cayman Islands exempted company; Special Purpose Acquisition Company (SPAC) / "Blank Check" company.
Objective: To effect a merger, share exchange, or asset acquisition with one or more businesses, primarily in the healthcare or healthcare-related sectors.
Status: No operating history or revenues to date. The company is a shell company with nominal assets consisting almost entirely of cash.
Key Financial Metrics
Pre-IPO Financial Position (as of Dec 31, 2025):
- Net Loss: $51,482 (from inception through Dec 31, 2025).
- Cash on Hand: $25,000.
- Working Capital Deficit: $279,478.
- Liabilities: $333,819 (including $120,619 promissory note to Sponsor and $206,034 accrued offering costs).
- IPO Proceeds: 17,250,000 Class A shares sold at $10.00/share = $172,500,000 gross proceeds.
- Private Placement: 497,500 shares sold to Sponsor at $10.00/share = $4,975,000 gross proceeds.
- Trust Account: $172,500,000 deposited ($10.00 per public share).
- Transaction Costs: $7,505,053 total ($1,725,000 cash underwriting fee, $5,175,000 deferred underwriting fee, $605,053 other costs).
- Working Capital Available: Approximately $2,375,000 held outside the trust account for operations.
- Class A Ordinary Shares: 17,747,500 issued and outstanding.
- Class B Ordinary Shares (Founder Shares): 4,312,500 issued and outstanding.
Material Changes vs. Prior Period
The reporting period covers the company's inception through December 31, 2025. The most significant material change occurred subsequent to the reporting period on January 26, 2026:
- Capitalization: Transitioned from a pre-IPO entity with a working capital deficit to a publicly traded company with $172.5 million in the Trust Account.
- Debt: The $120,619 promissory note outstanding at year-end was fully repaid on January 27, 2026, using IPO proceeds.
- Share Count: Issued 17,250,000 Class A shares and finalized the Class B share count (562,500 shares previously subject to forfeiture were retained after full exercise of the over-allotment option).
Guidance, Outlook, Risks, and Contingencies
Outlook and Timeline:
- Completion Window: The company has 24 months from the IPO closing (January 26, 2026) to complete an initial business combination. Deadline: January 26, 2028.
- Liquidity: Management believes funds outside the trust account ($2.375M) are sufficient to operate for at least 24 months. Additional financing may be required to complete a business combination or fund operations if costs exceed estimates.
- Redemption: Public shareholders may redeem shares for cash equal to the Trust Account balance (approx. $10.00/share plus interest) upon a business combination or liquidation.
- Blank Check Status: No operating history; investment is speculative.
- Liquidation Risk: If a business combination is not completed within 24 months, the company will liquidate and redeem public shares.
- Dilution: Founder shares were purchased at ~$0.006/share. Upon conversion, this creates significant dilution to public shareholders (implied value drop to ~$7.58/share in a base case scenario).
- Third-Party Claims: Trust account funds could be reduced by claims from creditors if waivers are not obtained or are unenforceable, though the Sponsor has agreed to indemnify the Trust Account (subject to limitations).
- Regulatory: Subject to SEC "2024 SPAC Rules" and potential CFIUS review for foreign investments.
- Working Capital Loans: Sponsor or affiliates may loan up to $1.5 million convertible into Private Placement Shares to fund transaction costs.
- Deferred Underwriting: $5,175,000 fee payable only upon successful completion of a business combination.
Investor Verification Checklist
- Trust Account Balance: Verify the current balance and interest earned in the Trust Account to confirm the per-share redemption value.
- Target Selection: Confirm if a target business has been identified and the status of due diligence.
- Redemption Rights: Review the specific terms regarding the 20% redemption cap for shareholders holding "Excess Shares" if a shareholder vote is required.
- Sponsor Indemnity: Assess the financial capacity of the Sponsor (Helix Holdings III LLC) to satisfy indemnification obligations if third-party claims reduce the Trust Account.
- Extension Provisions: Check for any amendments to the Articles of Association that might extend the 24-month completion window.
- Deferred Fees: Confirm the $5,175,000 deferred underwriting fee obligation and its impact on post-combination cash flow.